Oct. 18 (Bloomberg) -- Akzo Nobel NV, the Dutch chemicals maker that plans to sell shares of its pharmaceutical unit, said its most promising experimental drug may face delays after the latest clinical tests showed ``mixed'' results.
A Danish pharmaceutical company, H. Lundbeck A/S, maker of the antidepressant Lexapro, is putting its U.S. commercial headquarters, with 50 to 75 employees, in the Philadelphia area, officials said yesterday.